Conference Cochairs:
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York
Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas
Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

WEDNESDAY, SEPTEMBER 27
3:00 p.m.-8:30 p.m.  Registration Opens
America Ballroom Foyer

5:45 p.m.-7:30 p.m.  Welcome and Keynote Lectures
America North and Central Ballroom

  5:45 p.m.-5:55 p.m.  Welcome from Cochairs
  Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

  5:55 p.m.-6:00 p.m.  Welcome from Lead Supporter
  Andrew Rakeman, Lustgarten Foundation, Woodbury, New York

  6:00 p.m.-6:30 p.m.  Rising Star Keynote [CME Eligible]
  “RNA switches” in pancreatic cancer: Expression, splicing and RNA-based therapeutics
  Luisa F. Escobar-Hoyos, Yale School of Medicine, New Haven, Connecticut

  6:30 p.m.-6:45 p.m.  Lightning Presentations [CME Eligible]
  Xianghui Zou, Zucker School of Medicine, Manhasset, New York (A008)
  Yukihito Kuroda, University of Tsukuba, Tsukuba, Japan (A016)
  Sabine Naudin, International Agency for Research on Cancer, Lyon, France (A017)
  Deepti Mathur, Memorial Sloan Kettering Cancer Center, New York, New York (A060)
  Mehrdad Zarei, Case Western Reserve University, Cleveland, Ohio (A105)
  Kevin MacPherson, Oregon Health & Science University, Portland, Oregon (A118)

  6:45 p.m.-7:30 p.m.  Opening Keynote [CME Eligible]
  Novel insights into pancreatic cancer evolution from carcinogenesis to metastasis
  Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York

7:30 p.m.-9:00 p.m.  Poster Session A / Opening Reception
America South Ballroom

*Short talk selected from proffered abstracts
THURSDAY, SEPTEMBER 28
Agu
America Ballroom Foyer

7:00 a.m.–8:00 a.m. Career Roundtables Session 1
Independence AB Ballroom

Limited to 100 participants; attendance to the Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Participants will be asked to rotate tables every 20 minutes, providing the opportunity to network and interact with a diverse cadre of expert mentors.

<table>
<thead>
<tr>
<th>Table Topic and Mentors</th>
<th>Table Topic and Mentors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conducting Translational Research: How to Get Started</td>
<td>Collaborating with Industry</td>
</tr>
<tr>
<td>Kathleen McAndrews, UT MD Anderson Cancer Center</td>
<td>Erkut Borazanci, Honor Health Research Institute</td>
</tr>
<tr>
<td>Choosing a Career Path: Academia vs Industry (1 of 2)</td>
<td>Starting Your Lab</td>
</tr>
<tr>
<td>Leny Gocheva, Break Through Cancer</td>
<td>Jason R. Pitarresi, University of Massachusetts Medical School</td>
</tr>
<tr>
<td>Paul Kurywchak, Skipper BioMed LLC</td>
<td></td>
</tr>
<tr>
<td>Choosing a Career Path: Academia vs Industry (2 of 2)</td>
<td>Getting Tenure</td>
</tr>
<tr>
<td>Laura Wood, Johns Hopkins</td>
<td>Kenneth Olive, Herbert Irving Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Harmeed Dhani, Biological Dynamics</td>
<td>Rushika Perera, University of California San Francisco</td>
</tr>
<tr>
<td>How to Get a Paper Published</td>
<td>Balancing Clinical and Research Life</td>
</tr>
<tr>
<td>Christine Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center</td>
<td>Jashodeep Datta, Univ. of Miami Sylvester Comprehensive Cancer Center</td>
</tr>
<tr>
<td>Ben Stanger, University of Pennsylvania</td>
<td>Cristina Ferrone, Cedars-Sinai Medical Center</td>
</tr>
<tr>
<td>Harmony Turk, Executive Editor Cancer Research</td>
<td></td>
</tr>
<tr>
<td>How to Write a Grant (1 of 2)</td>
<td>Entrepreneurship</td>
</tr>
<tr>
<td>Peter Allen, Duke University School of Medicine</td>
<td>David Ting, Massachusetts General Hospital</td>
</tr>
<tr>
<td>Mandar Mazumdar, Yale School of Medicine</td>
<td>Manuel Hidalgo, Weil Cornell Medicine</td>
</tr>
<tr>
<td>How to Write a Grant (2 of 2)</td>
<td>Encouraging Diversity in Your Team</td>
</tr>
<tr>
<td>Marina Pasca di Magliano, University of Michigan Medical School</td>
<td>Zobeida Cruz-Montserrat, The Ohio State University</td>
</tr>
<tr>
<td>Kirsten Bryant, UNC Lineberger Comprehensive Cancer Center</td>
<td></td>
</tr>
</tbody>
</table>
8:15 a.m.–10:00 a.m.  Plenary Session 1: Epidemiology and Early Detection in Honor of Dr. Gloria Petersen [CME Eligible]

America North and Central Ballroom

Session Chair: Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas

8:15 a.m.-8:35 a.m.  
Genetic epidemiology of pancreatic cancer: Past, present and future
Alison Klein, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

8:35 a.m.-8:40 a.m.  Q&A/Discussion

8:40 a.m.-8:50 a.m.  
Implementation of a real-time AI-guided navigation service for pancreas cancer*
Kristen M. John, Zucker School of Medicine, New Hyde Park, New York

8:50 a.m.- 8:55 a.m.  Q&A/Discussion

8:55 a.m.-9:15 a.m.  
Molecular detection of pancreatic cancer using methylated DNA markers
Shounak Majumder, Mayo Clinic, Rochester, Minnesota

9:15 a.m.- 9:20 a.m.  Q&A/Discussion

9:20 a.m.-9:30 a.m.  
Deep proteomics identifies novel biomarker candidates and molecular pathways of pancreatic cancer-related diabetes*
Lucy Oldfield, University of Liverpool, Liverpool, United Kingdom

9:30 a.m.- 9:35 a.m.  Q&A/Discussion

9:35 a.m.-9:55 a.m.  
Emerging trends and risk factors for pancreatic cancer in multiethnic populations
V. Wendy Setiawan, USC Norris Comprehensive Cancer Center, Los Angeles, California

9:55 a.m.- 10:00 a.m. Q&A/Discussion

10:00 a.m.-10:30 a.m.  Break
America Ballroom Foyer

10:30 a.m.–12:15 p.m.  Plenary Session 2: Diversity and Disparities [CME Eligible]

America North and Central Ballroom

Session Chair: Nicolette J. Rodriguez, Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts

10:30 a.m.-10:50 a.m.  
Advancing equity in access to PDAC cancer genetics and prevention
Nicolette J. Rodriguez, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts

10:50 a.m.-11:00 a.m.  Q&A/Discussion

*Short talk selected from proffered abstracts
11:00 a.m.-11:10 a.m. **Addressing disparities in the Native American population in Oregon:**
The development of multi-disciplinary frameworks to study pancreatic ductal adenocarcinoma in Native American communities*
Jared Delaney, Oregon Health & Science University, Portland, Oregon

11:10 a.m.-11:15 a.m. Q&A/Discussion

11:15 a.m.-11:35 a.m. **Diversity and disparity in pancreatic cancer care**
Jose Trevino, VCU Massey Cancer Center, Richmond, Virginia

11:35 a.m.-11:45 a.m. Q&A/Discussion

11:45 a.m.-12:05 p.m. **Who does the cutting-edge leave behind? Inequities at the frontiers of pancreas cancer care**
Ugwuji N. Maduekwe, Medical College of Wisconsin, Milwaukee, Wisconsin

12:05 p.m.-12:15 p.m. Q&A/Discussion

**Lunch on Own**

**Plenary Session 3: Clinical Updates [CME Eligible]**
America North and Central Ballroom

*Session Chair: Talia Golan, Sheba Medical Center, Ramat Gan, Israel*

2:15 p.m.-2:35 p.m. **Spectrum of response to platinum and PARP inhibitors in HR-deficient pancreatic cancer**
Talia Golan, Sheba Medical Center, Ramat Gan, Israel

2:35 p.m.-2:45 p.m. Q&A/Discussion

2:45 p.m.-2:55 p.m. **Therapeutic development platform for pancreatic cancer in the UK national health service: Lessons learned and initial results from Precision-Panc***
David K. Chang, University of Glasgow, Glasgow, United Kingdom

2:55 p.m.-3:00 p.m. Q&A/Discussion

3:00 p.m.-3:10 p.m. **CheMo4METPANC: Combination Chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naïve PANCreactic adenocarcinoma***
Gulam A. Manji, Columbia University Irving Medical Center/New York Presbyterian, New York, New York

3:10 p.m.-3:15 p.m. Q&A/Discussion

3:15 p.m.-3:35 p.m. **Pancreatic cancer clinical updates**
Cristina R. Ferrone, Cedars-Sinai, Los Angeles, California

3:35 p.m.-3:45 p.m. Q&A/Discussion

*Short talk selected from proffered abstracts*
3:45 p.m.-3:55 p.m.  **CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study**
*Teresa Macarulla, Vall d'Hebrón University Hospital, Barcelona, Spain*

3:55 p.m.- 4:00 p.m.  Q&A/Discussion

4:00 p.m.-4:20 p.m.  **Clinical updates: Refining the role of radiation in the treatment of pancreas cancer**
*Manisha Palta, Duke Cancer Center, Durham, North Carolina*

4:20 p.m.- 4:30 p.m.  Q&A/Discussion

4:30 p.m.-4:40 p.m.  **Lightning Presentations**
Brandon Huffman, Dana-Farber Cancer Institute, Boston, Massachusetts (B005)
Deepika Bhullar, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California (B013)
Amanda Decker-Farrell, Columbia University Irving Medical Center, New York, New York (B015)
Megan Hoffman, Dana-Farber Cancer Institute, Boston, Massachusetts (B016)
Keilah Garcia Netto, University of New South Wales, Sydney, Australia (B062)

4:40 p.m.-6:40 p.m.  **Poster Session B / Reception**
America South Ballroom

**FRIDAY, SEPTEMBER 29**
7:00 a.m.–8:00 a.m.  **Breakfast**
America Ballroom Foyer

8:00 a.m.–10:00 a.m.  **Plenary Session 4: Systems Biology, Big Data, and Metastasis [CME Eligible]**
America North and Central Ballroom

*Session Chair: Steven Gallinger, Ontario Institute for Cancer Research, Toronto, Canada*

8:00 a.m.-8:20 a.m.  **Developmental and MAPK-responsive programs drive distinct malignant subtypes and dependencies in pancreatic cancer**
*Andrea Califano, Columbia University, New York, New York*

8:20 a.m.-8:30 a.m.  Q&A/Discussion

8:30 a.m.-8:40 a.m.  **Unravelling the epigenetic landscape of pancreatic cancer: The role of cancer-associated fibroblasts**
*Catarina Pelicano, CRUK University of Cambridge, Cambridge, United Kingdom*

8:40 a.m.- 8:45 a.m.  Q&A/Discussion
8:45 a.m.-9:05 a.m.  **Forecasting pancreatic carcinogenesis through spatial multi-omics**  
Elana J. Fertig, Johns Hopkins University, Baltimore, Maryland

9:05 a.m.- 9:15 a.m.  Q&A/Discussion

9:15 a.m.-9:25 a.m.  **Spatial mapping of transcriptomic and lineage diversity in metastatic pancreatic cancer***
Jimin Min, UT MD Anderson Cancer Center, Houston, Texas

9:25 a.m.- 9:30 a.m.  Q&A/Discussion

9:30 a.m.-9:50 a.m.  **What the surgeon has learned from pancreas cancer genomics, and vice versa**
Steven Gallinger, Ontario Institute for Cancer Research, Toronto, Canada

9:50 a.m.- 10:00 a.m.  Q&A/Discussion

**10:00 a.m.—10:30 a.m.**  
**Break**

America Ballroom Foyer

**10:30 a.m.—12:30 p.m.**  
**Plenary Session 5: Metabolic Perturbations [CME Eligible]**
America North and Central Ballroom

*Session Chair: Rushika Perera, University of California San Francisco, San Francisco, California*

10:30 a.m.-10:50 a.m.  **Feeding the flames of pancreatic cancer**
Mandar Muzumdar, Yale School of Medicine, New Haven, Connecticut

10:50 a.m.-11:00 a.m.  Q&A/Discussion

11:00 a.m.-11:10 a.m.  **Pancreatic cancer cachexia is mediated by tumor-derived PTHrP***
Jason R. Pitarresi, University of Massachusetts Medical School, Worcester, Massachusetts

11:10 a.m.-11:15 a.m.  Q&A/Discussion

11:15 a.m.-11:35 a.m.  **Identifying and disabling the metabolic engines that fuel pancreatic cancer**
Rushika Perera, University of California San Francisco, San Francisco, California

11:35 a.m.-11:45 a.m.  Q&A/Discussion

11:45 a.m.-11:55 a.m.  **Uridine-to-ribose axis supports glucose-restricted pancreatic cancer***
Zeribe C. Nwosu, University of Michigan, Ann Arbor, Michigan

11:55 a.m.-12:00 p.m.  Q&A/Discussion

12:00 p.m.-12:20 p.m.  **Molecular mechanisms of obesity-associated pancreatic ductal adenocarcinoma**
Zobeida Cruz-Monserrate, The Ohio State University, Columbus, Ohio

12:20 p.m.-12:30 p.m.  Q&A/Discussion

*Short talk selected from proffered abstracts*
12:30 p.m.–2:30 p.m.  Lunch on Own

1:00 p.m.–2:00 p.m.  Career Roundtables Session 2
Independence AB Ballroom

Limited to 100 participants; attendance to the Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Participants will be asked to rotate tables every 20 minutes, providing the opportunity to network and interact with a diverse cadre of expert mentors.

<table>
<thead>
<tr>
<th>Table Topic and Mentors</th>
<th>Table Topic and Mentors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Conducting Translational Research: How to Get Started</strong></td>
<td><strong>Collaborating with Industry</strong></td>
</tr>
<tr>
<td>Steven Gallinger, Ontario Institute for Cancer Research</td>
<td>Julian Adams, Stand Up To Cancer</td>
</tr>
<tr>
<td></td>
<td>Timothy Donahue, UCLA David Geffen School of Medicine</td>
</tr>
<tr>
<td><strong>Choosing a Career Path: Academia vs Industry (1 of 2)</strong></td>
<td><strong>Starting Your Lab</strong></td>
</tr>
<tr>
<td>Gargi Basu, EXACT Sciences Corp.</td>
<td>Yang Chen, UT MD Anderson Cancer Center</td>
</tr>
<tr>
<td>Arnav Mehta, MGH/Harvard Medical School</td>
<td>William Freed-Pastor, Dana-Farber Cancer Institute</td>
</tr>
<tr>
<td><strong>Choosing a Career Path: Academia vs Industry (2 of 2)</strong></td>
<td><strong>Getting Tenure</strong></td>
</tr>
<tr>
<td>John Morris, University of North Carolina at Chapel Hill</td>
<td>Ingunn Stromnes, University of Minnesota</td>
</tr>
<tr>
<td></td>
<td>Eric Collisson, University of California San Francisco</td>
</tr>
<tr>
<td><strong>How to Get a Paper Published</strong></td>
<td><strong>Balancing Clinical and Research Life</strong></td>
</tr>
<tr>
<td>Direna Alonso Curbelo, Institute for Research in Biomedicine - IRB Barcelona</td>
<td>Filip Bednar, University of Michigan</td>
</tr>
<tr>
<td>Anirban Maitra, UT MD Anderson</td>
<td>Eileen O’Reilly, Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Avital (Tali) Lev, Senior Editor <em>Cancer Discovery</em></td>
<td></td>
</tr>
<tr>
<td><strong>How to Write a Grant (1 of 2)</strong></td>
<td><strong>Entrepreneurship</strong></td>
</tr>
<tr>
<td>Rosalie Sears, OHSU</td>
<td>Jen Jen Yeh, University of North Carolina at Chapel Hill</td>
</tr>
<tr>
<td>Howard Crawford, Henry Ford Health System</td>
<td></td>
</tr>
<tr>
<td><strong>How to Write a Grant (2 of 2)</strong></td>
<td><strong>Encouraging Diversity in Your Team</strong></td>
</tr>
<tr>
<td>Andy Aguirre, Dana-Farber Cancer Institute</td>
<td>Brittany Allen-Petersen, Purdue University</td>
</tr>
<tr>
<td>John Brody, OHSU</td>
<td>Debora Vendramini Costa, Henry Ford Health System</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2:30 p.m.–4:40 p.m.  Plenary Session 6: RAS, Oncogene Addiction, & Other Targeted Therapies [CME Eligible]
America North and Central Ballroom

*Session Chair: Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon*

*Short talk selected from proffered abstracts*
2:30 p.m.-2:50 p.m.  KRAS inhibition and the TME: Two for the price of one
Ben Z. Stanger, University of Pennsylvania, Philadelphia, Pennsylvania

2:50 p.m.-3:00 p.m.  Q&A/Discussion

3:00 p.m.-3:10 p.m.  KRAS mutant-specific interactions reveal mechanisms in pancreatic cancer tumorigenesis and metabolic function*
G. Aaron Hobbs, Medical University of South Carolina, Charleston, South Carolina

3:10 p.m.-3:15 p.m.  Q&A/Discussion

3:15 p.m.-3:35 p.m.  Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer
Ronald A. DePinho, UT MD Anderson Cancer Center, Houston, Texas

3:35 p.m.-3:45 p.m.  Q&A/Discussion

3:45 p.m.-3:55 p.m.  Targeting CDK7/9 in basal pancreatic cancer*
Sita Kugel, Fred Hutch Cancer Center, Seattle, Washington

3:55 p.m.-4:00 p.m.  Q&A/Discussion

4:00 p.m.-4:20 p.m.  MYC’s role in liver metastatic poor outcome pancreatic ductal adenocarcinoma
Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon

4:20 p.m.-4:30 p.m.  Q&A/Discussion

4:30 p.m.-4:40 p.m.  Lightning Presentations
Peter Yu, NYU Grossman School of Medicine, New York, New York (C054)
Kyle McAndrews, University of Nebraska Medical Center, Omaha, Nebraska (C055)
Johann Gout, Institute for Molecular Oncology and Stem Cell Biology, Ulm, Germany (C061)
Ifeanyichukwu Ogobuiro, University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida (C065)

4:40 p.m.-6:40 p.m.  Poster Session C / Reception
America South Ballroom

SATURDAY, SEPTEMBER 30

7:00 a.m.–8:00 a.m.  Breakfast
America Ballroom Foyer

8:00 a.m.–10:00 a.m.  Plenary Session 7: Model Systems [CME Eligible]
America North and Central Ballroom

*Short talk selected from proferred abstracts
Session Chair: Jonathan R. Brody, OHSU Knight Cancer Institute, Portland, Oregon

8:00 a.m.-8:20 a.m. **Addressing the hallmarks of pancreatic cancer**
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
8:20 a.m.-8:30 a.m. Q&A/Discussion

8:30 a.m.-8:40 a.m. **Single-cell mapping reveals a common origin for diverse subtypes of pancreatic cancer** *
Nirakar Rajbhandari, University of California San Diego, La Jolla, California
8:40 a.m.- 8:45 a.m. Q&A/Discussion

8:45 a.m.-9:05 a.m. **Understanding KRAS cancer initiation and progression**
Lukas E. Dow, Weill Cornell Medicine, New York, New York
9:05 a.m.- 9:15 a.m. Q&A/Discussion

9:15 a.m.-9:25 a.m. **Ex vivo models of pancreatic cancer that recapitulate the metabolic tumor microenvironment identify glycine as a chemoresistance-inducing oncometabolite** *
Alexander Muir, University of Chicago, Chicago, Illinois
9:25 a.m.- 9:30 a.m. Q&A/Discussion

9:30 a.m.-9:50 a.m. **PDAC’s response to a stressful environment reveals targets and resistance mechanisms**
Jonathan R. Brody, OHSU Knight Cancer Institute, Portland, Oregon
9:50 a.m.- 10:00 a.m. Q&A/Discussion

10:00 a.m.—10:15 a.m. **Break**
America Ballroom Foyer

10:15 a.m.—12:15 p.m. **Plenary Session 8: Therapeutic Opportunities in Tumor Stroma and Immune Microenvironments [CME Eligible]**
America North and Central Ballroom

**Session Chair: Ingunn M. Stromnes, University of Minnesota, Minneapolis, Minnesota**

10:15 a.m.-10:35 a.m. **Pancreatic cancer – exceptional survivors to RNA vaccines**
Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
10:35 a.m.-10:45 a.m. Q&A/Discussion

10:45 a.m.-10:55 a.m. **Adenosine inhibits STING driven anti-tumor immunity in pancreatic cancer** *
Alykhan Premji, University of California Los Angeles, Los Angeles, California

*Short talk selected from proffered abstracts*
11:55 a.m.-11:00 a.m. Q&A/Discussion

11:00 a.m.-11:20 a.m. Tumor microbes driving therapies responses
Florenicia McAllister, UT MD Anderson Cancer Center, Houston, Texas
11:20 a.m.-11:30 a.m. Q&A/Discussion

11:30 a.m.-11:40 a.m. Neutrophil-intrinsic tumor necrosis factor (TNF) is a novel driver of T-cell and cancer-associated fibroblast (CAF) dysfunction in pancreatic cancer*
Anna Bianchi, University of Miami Miller School of Medicine, Miami, Florida
11:40 a.m.-11:45 a.m. Q&A/Discussion

11:45 a.m.-12:05 p.m. Elucidating mechanisms of immunotherapy response in pancreatic cancer
Ingunn M. Stromnes, University of Minnesota, Minneapolis, Minnesota
12:05 p.m.-12:15 p.m. Q&A/Discussion

12:15 p.m.-12:20 p.m. Closing Remarks
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, New York
Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, Texas
Rosalie C. Sears, Oregon Health & Science University, Portland, Oregon
Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

*Short talk selected from proffered abstracts